New Zealand Launches Genomic Testing Pilot to Reduce Delays for Cancer and Rare Disease Patients

New Zealand is launching a two-year clinical pilot to deliver genomic testing locally for people with cancer and rare disorders, reducing reliance on overseas laboratories and cutting waiting times. Announced on 18 March 2026, the initiative led by Health New Zealand aims to improve diagnostic speed, strengthen clinical capability, and inform the development of a coordinated national genomics service. The pilot also focuses on secure management of sensitive genomic data within New Zealand’s health system.

According to the official government announcement, genomic tests for certain cancers and rare disorders have often been sent offshore, contributing to delays that can affect treatment decisions and prolong uncertainty for patients.

Reducing delays through local genomic testing

Health Minister Simeon Brown said bringing testing onshore addresses a longstanding bottleneck in care pathways. He noted that delays in genomic sequencing can have a direct impact on when patients begin treatment or receive a confirmed diagnosis.

“Too many Kiwis are left waiting for answers because their genomic tests are sent overseas – delays that can affect treatment decisions or prolong years of uncertainty,” — Simeon Brown, Health Minister, New Zealand Government

The pilot is designed to support health system targets by enabling cancer patients to receive treatment sooner and reducing time spent waiting for specialist care. It also seeks to build domestic expertise in genomic medicine, supporting clinicians to deliver more precise and timely care.

Scope of the two-year pilot programme

Health New Zealand is partnering with Illumina to deliver the trial, allowing advanced genomic technologies to be assessed while capability is developed within the public health system. The programme will trial two complementary testing approaches:

• Whole Genome Sequencing: to support diagnosis of rare and inherited disorders.
• Comprehensive Genomic Profiling: to help guide cancer diagnosis and treatment decisions.

Testing for rare disorders will cover a range of conditions, including metabolic, connective tissue, eye, hearing and renal disorders. Work is continuing to determine the specific focus areas for cancer-related testing.

Cost, capacity and data governance considerations

New Zealand currently spends more than NZ$4 million each year sending over 4,000 genomic tests overseas. The pilot will process more than 6,000 samples over two years, consolidating existing workflows and introducing new tests. By the end of the trial, around half of tests currently sent offshore are expected to be completed domestically.

If adopted nationally, government modelling suggests the approach could generate around NZ$5 million in operational savings over five years, while ensuring genomic data is managed securely within New Zealand. Alongside clinical outcomes, the pilot will assess workforce readiness, operational efficiency, and the systems needed to support genomic data governance.

These system-level considerations align with wider digital health reforms, including New Zealand’s 10-year digital healthcare plan, which emphasises patient-centred services, data security and integrated digital infrastructure.

Implications for patients with rare disorders

The announcement coincides with Rare Disorders Month, underscoring the importance of timely diagnosis for thousands of New Zealanders living with uncommon conditions. Faster access to genomic testing can reduce years of uncertainty for patients and families and support earlier, more appropriate interventions.

“This pilot is about getting Kiwis answers faster and building a genomics testing service New Zealand can be proud of,” — Simeon Brown, Health Minister, New Zealand Government

As genomic medicine becomes increasingly integrated with digital tools and data-driven care models, the pilot also complements broader efforts to expand advanced technologies across the health sector, including the use of analytics and automation highlighted in recent healthcare innovation initiatives.